WHO ICTRP trial
A POST-MARKET EVALUATION OF THE CE MARK APPROVED DESolve® NOVOLIMUS ELUTING…
DRKS00006144 · German Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | DRKS00006144 |
|---|---|
| Public title | A POST-MARKET EVALUATION OF THE CE MARK APPROVED DESolve® NOVOLIMUS ELUTING BIORESORBABLE CORONARY SCAFFOLD SYSTEM IN THE TREATMENT OF PATIENTS WITH DE NOVO NATIVE CORONARY ARTERY LESIONS |
| Scientific title | A POST-MARKET EVALUATION OF THE CE MARK APPROVED DESolve® NOVOLIMUS ELUTING BIORESORBABLE CORONARY SCAFFOLD SYSTEM IN THE TREATMENT OF PATIENTS WITH DE NOVO NATIVE CORONARY ARTERY LESIONS - DESolve PMCF Study |
| Primary sponsor | Elixir Medical Corporation |
| Registry | German Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | interventional |
| Countries | Germany;Italy |
| Conditions | I25;Chronic ischaemic heart disease |
| Interventions | Group 1: DESolve® Novolimus Eluting Bioresorbable Coronary Scaffold System |
| Registration date | Dec 5, 2014 |
| Target size | 100 |
| Secondary IDs | NCT02013349 |
| Registry page | drks.de |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: